Primary biliary cirrhosis (PBC) is an immune-mediated chronic cholestatic liver disease with a slowly progressive course. Without treatment, most patients eventually develop fibrosis and cirrhosis of the liver and may need liver transplantation in the late stage of disease. PBC primarily affects women (female preponderance 9–10:1) with a prevalence of up to 1 in 1,000 women over 40 years of age. Common symptoms of the disease are fatigue and pruritus, but most patients are asymptomatic at first presentation. The diagnosis is based on sustained elevation of serum markers of cholestasis, i.e., alkaline phosphatase and gamma-glutamyl transferase, and the presence of serum antimitochondrial antibodies directed against the E2 subunit of the pyruvate dehydrogenase complex. Histologically, PBC is characterized by florid bile duct lesions with damage to biliary epithelial cells, an often dense portal inflammatory infiltrate and progressive loss of small intrahepatic bile ducts. Although the insight into pathogenetic aspects of PBC has grown enormously during the recent decade and numerous genetic, environmental, and infectious factors have been disclosed which may contribute to the development of PBC, the precise pathogenesis remains enigmatic. Ursodeoxycholic acid (UDCA) is currently the only FDA-approved medical treatment for PBC. When administered at adequate doses of 13–15 mg/kg/day, up to two out of three patients with PBC may have a normal life expectancy without additional therapeutic measures. The mode of action of UDCA is still under discussion, but stimulation of impaired hepatocellular and cholangiocellular secretion, detoxification of bile, and antiapoptotic effects may represent key mechanisms. One out of three patients does not adequately respond to UDCA therapy and may need additional medical therapy and/or liver transplantation. This review summarizes current knowledge on the clinical, diagnostic, pathogenetic, and therapeutic aspects of PBC.
Unsere Produktempfehlungen
e.Med Interdisziplinär
Kombi-Abonnement
Mit e.MedInterdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.
Nicht verpassen: e.Med bis 13. März 2019 100€ günstiger im ersten Jahr!
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Nicht verpassen: e.Med bis 13. März 2019 100€ günstiger im ersten Jahr!
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
Nicht verpassen: e.Med bis 13. März 2019 100€ günstiger im ersten Jahr!
Addison T, Gull W (1851) On a certain affection of the skin-vitiligoidea-α-plana β-tuberosa. Guys Hosp Rep 7:G265–G277
3.
Ahrens EH Jr, Kunkel HG (1949) The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis. J Clin Invest 28(6, Pt. 2):1565–1574. doi:
10.1172/JCI102222PubMedCrossRef
4.
Nishio A, Keeffe EB, Gershwin ME (2002) Immunopathogenesis of primary biliary cirrhosis. Semin Liver Dis 22(3):291–302. doi:
10.1055/s-2002-34506PubMedCrossRef
5.
Yeaman SJ, Kirby JA, Jones DE (2000) Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev 174:238–249. doi:
10.1034/j.1600-0528.2002.00021h.xPubMedCrossRef
6.
Terasaki S et al (1993) Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 17(2):206–212. doi:
10.1002/hep.1840170208PubMedCrossRef
7.
Gershwin ME, Mackay IR (2008) The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47(2):737–745. doi:
10.1002/hep.22042PubMedCrossRef
Corpechot C et al (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128(2):297–303. doi:
10.1053/j.gastro.2004.11.009PubMedCrossRef
12.
Pares A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130(3):715–720. doi:
10.1053/j.gastro.2005.12.029PubMedCrossRef
13.
Corpechot C et al (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48(3):871–877. doi:
10.1002/hep.22428PubMedCrossRef
14.
Kuiper EM et al (2009) Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136(4):1281–1287. doi:
10.1053/j.gastro.2009.01.003PubMedCrossRef
15.
Kaplan MM (1987) Primary biliary cirrhosis. N Engl J Med 316(9):521–528
PubMed
16.
Hamlyn AN, Sherlock S (1974) The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales. Gut 15(6):473–479. doi:
10.1136/gut.15.6.473PubMedCrossRef
17.
Danielsson A, Boqvist L, Uddenfeldt P (1990) Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 11(3):458–464. doi:
10.1002/hep.1840110317PubMedCrossRef
18.
Witt-Sullivan H et al (1990) The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 12(1):98–105. doi:
10.1002/hep.1840120116PubMedCrossRef
19.
Kim WR et al (2000) Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119(6):1631–1636. doi:
10.1053/gast.2000.20197PubMedCrossRef
20.
Watson RG et al (1995) Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. Gut 36(6):927–930. doi:
10.1136/gut.36.6.927PubMedCrossRef
21.
James OF et al (1999) Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 30(2):390–394. doi:
10.1002/hep.510300213PubMedCrossRef
Lazaridis KN, Talwalkar JA (2007) Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 41(5):494–500. doi:
10.1097/01.mcg.0000225653.07932.8fPubMedCrossRef
24.
Karvonen M et al (1993) A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group. Diabetologia 36(10):883–892. doi:
10.1007/BF02374468PubMedCrossRef
25.
Prince MI, Jones DE (2000) Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J 76(894):199–206. doi:
10.1136/pmj.76.894.199PubMedCrossRef
26.
Nakano T et al (2002) Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol Res 22(4):250–260. doi:
10.1016/S1386-6346(01)00148-6PubMedCrossRef
27.
Prince M et al (2002) Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123(4):1044–1051. doi:
10.1053/gast.2002.36027PubMedCrossRef
28.
Heathcote EJ (2000) Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31(4):1005–1013. doi:
10.1053/he.2000.5984PubMedCrossRef
29.
EASL (2009) Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. doi:
10.1016/j.jhep2009.04.009
30.
Jorde R, Rekvig OP, Bostad L (1986) A follow-up study of 68 patients with anti-mitochondrial antibodies (AMA). Acta Med Scand 220(3):241–247
PubMed
31.
Shapiro JM, Smith H, Schaffner F (1979) Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20(2):137–140. doi:
10.1136/gut.20.2.137PubMedCrossRef
Elferink RP et al (1998) Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. J Clin Invest 102(9):1749–1757. doi:
10.1172/JCI3597PubMedCrossRef
34.
Su TC, Hwang JJ, Kao JH (2007) Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med 357(15):1561–1562. doi:
10.1056/NEJMc071467PubMedCrossRef
35.
Poupon RE et al (1993) Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 17(4):577–582. doi:
10.1002/hep.1840170408PubMedCrossRef
36.
Mitchison HC et al (1986) Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 6(6):1279–1284. doi:
10.1002/hep.1840060609PubMedCrossRef
Brunner G, Klinge O (1987) A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis). Dtsch Med Wochenschr 112(38):1454–1458. doi:
10.1055/s-2008-1068269PubMedCrossRef
39.
Ben-Ari Z, Dhillon AP, Sherlock S (1993) Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 18(1):10–15. doi:
10.1002/hep.1840180103PubMedCrossRef
40.
Michieletti P et al (1994) Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 35(2):260–265. doi:
10.1136/gut.35.2.260PubMedCrossRef
41.
Taylor SL, Dean PJ, Riely CA (1994) Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 18(1):91–99. doi:
10.1097/00000478-199401000-00009PubMed
42.
Lacerda MA et al (1995) Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 90(2):247–249
PubMed
Shimoda S et al (2008) CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun 31(2):110–115. doi:
10.1016/j.jaut.2008.05.003PubMedCrossRef
45.
Lucena JF et al (2003) A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 124(4):1037–1042. doi:
10.1053/gast.2003.50144PubMedCrossRef
46.
Sherlock S, Scheuer PJ (1973) The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 289(13):674–678
PubMedCrossRef
47.
Kikuchi K et al (2005) Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology 128(2):304–312. doi:
10.1053/j.gastro.2004.11.005PubMedCrossRef
Blachar A, Federle MP, Brancatelli G (2001) Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. Radiology 220(2):329–336
PubMed
50.
Abenavoli L, Corpechot C, Poupon R (2007) Elastography in hepatology. Can J Gastroenterol 21(12):839–842
PubMed
51.
Corpechot C et al (2006) Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 43(5):1118–1124. doi:
10.1002/hep.21151PubMedCrossRef
52.
Ludwig J, Dickson ER, McDonald GS (1978) Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 379(2):103–112. doi:
10.1007/BF00432479PubMedCrossRef
53.
Scheuer PJ (1983) Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J 59(Suppl 4):106–115. doi:
10.1136/pgmj.59.688.106PubMed
54.
Roll J et al (1983) The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 308(1):1–7
PubMedCrossRef
Prince MI et al (2004) Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53(6):865–870. doi:
10.1136/gut.2003.023937PubMedCrossRef
Laurin JM et al (1994) The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol 89(10):1840–1843
PubMed
59.
Cauch-Dudek K et al (1998) Fatigue in primary biliary cirrhosis. Gut 43(5):705–710
PubMedCrossRef
60.
Newton JL et al (2008) A predictive model for fatigue and its aetiologica associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol 6:228–233. doi:
10.1016/j.cgh.2007.11.021PubMedCrossRef
Colina F et al (1992) Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 102(4 Pt 1):1319–1324
PubMed
65.
Huet PM et al (2008) Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 135(5):1552–1560. doi:
10.1053/j.gastro.2008.07.019PubMedCrossRef
66.
Mayo MJ (2008) Portal hypertension in primary biliary cirrhosis: a potentially reversible harbinger of demise. Gastroenterology 135(5):1450–1451. doi:
10.1053/j.gastro.2008.09.041PubMedCrossRef
67.
Springer JE et al (2000) Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 118(1):145–151. doi:
10.1016/S0016-5085(00)70423-9PubMedCrossRef
68.
Hodgson SF et al (1985) Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 103(6 (Pt 1)):855–860
PubMed
69.
Epstein O et al (1982) The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology 83(6):1177–1182
PubMed
Kingham JG, Parker DR (1998) The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 42(1):120–122
PubMed
72.
Munoz SJ et al (1989) Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology 9(4):525–531. doi:
10.1002/hep.1840090403PubMedCrossRef
Wolke AM et al (1984) Malignancy in primary biliary cirrhosis. Incidence of breast cancer in affected women. High Am J Med 76(6):1075–1078. doi:
10.1016/0002-9343(84)90861-1
75.
Goudie BM et al (1985) Breast cancer in women with primary biliary cirrhosis. Br Med J (Clin Res Ed) 291(6509):1597–1598. doi:
10.1136/bmj.291.6509.1597CrossRef
76.
Loof L et al (1994) Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. Hepatology 20(1 Pt 1):101–104
PubMed
77.
Jones DE et al (1997) Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26(5):1138–1142. doi:
10.1002/hep.510260508PubMedCrossRef
78.
Nijhawan PK et al (1999) Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 29(5):1396–1398. doi:
10.1002/hep.510290511PubMedCrossRef
79.
Shibuya A et al (2002) Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35(5):1172–1178. doi:
10.1053/jhep.2002.33157PubMedCrossRef
80.
Crowe JP et al (1980) Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology 78(6):1437–1441
PubMed
81.
Mang FW et al (1997) Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 12(3):167–170. doi:
10.1007/PL00009532PubMedCrossRef
82.
Reynolds TB et al (1971) Primary biliary cirrhosis with scleroderma. Raynaud's phenomenon and telangiectasia. New syndrome. Am J Med 50(3):302–312. doi:
10.1016/0002-9343(71)90218-XPubMedCrossRef
83.
Bush A et al (1987) Primary biliary cirrhosis and ulcerative colitis. Gastroenterology 92(6):2009–2013
PubMed
84.
Jones DE (2007) Pathogenesis of primary biliary cirrhosis. Gut 56(11):1615–1624
PubMed
Invernizzi P, Gershwin ME (2008) The genetic basis of primary biliary cirrhosis: premises, not promises. Gastroenterology 135(4):1044–1047. doi:
10.1053/j.gastro.2008.08.020PubMedCrossRef
88.
Invernizzi P et al (2005) From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol 3(5):401–410. doi:
10.1016/S1542-3565(04)00678-0PubMedCrossRef
89.
Selmi C et al (2004) Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 127(2):485–492. doi:
10.1053/j.gastro.2004.05.005PubMedCrossRef
90.
Jones DE et al (1999) Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 30(3):402–407. doi:
10.1016/S0168-8278(99)80097-XPubMedCrossRef
91.
Parikh-Patel A et al (1999) The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. Clin Immunol 91(2):206–218. doi:
10.1006/clim.1999.4690PubMedCrossRef
Underhill J et al (1992) Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 16(6):1404–1408. doi:
10.1002/hep.1840160616PubMedCrossRef
94.
Donaldson PT et al (2006) HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 44(3):667–674. doi:
10.1002/hep.21316PubMedCrossRef
Wassmuth R et al (2002) HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhosis. Tissue Antigens 59(5):381–387. doi:
10.1034/j.1399-0039.2002.590504.xPubMedCrossRef
97.
Stone J et al (2002) Human leukocyte antigen class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol 36(1):8–13. doi:
10.1016/S0168-8278(01)00237-9PubMedCrossRef
98.
Onishi S et al (1994) DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 21(6):1053–1060. doi:
10.1016/S0168-8278(05)80617-8PubMedCrossRef
99.
Liu HY et al (2005) Analysis of HLA alleles polymorphism in Chinese patients with primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 13(6):410–413
PubMed
100.
Gores GJ et al (1987) Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. Hepatology 7(5):889–892. doi:
10.1002/hep.1840070516PubMedCrossRef
101.
Invernizzi P et al (2003) Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol 38(4):401–406. doi:
10.1016/S0168-8278(02)00440-3PubMedCrossRef
102.
Seki T et al (1993) Association of primary biliary cirrhosis with human leukocyte antigen DPB1*0501 in Japanese patients. Hepatology 18(1):73–78. doi:
10.1002/hep.1840180113PubMedCrossRef
103.
Invernizzi P et al (2008) Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology 48(6):1906–1912. doi:
10.1002/hep.22567PubMedCrossRef
Ueda H et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423(6939):506–511. doi:
10.1038/nature01621PubMedCrossRef
106.
Chistiakov DA, Turakulov RI (2003) CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 31(1):21–36. doi:
10.1677/jme.0.0310021PubMedCrossRef
Schott E et al (2007) Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 19(11):947–951. doi:
10.1097/MEG.0b013e3282efa240PubMedCrossRef
111.
Juran BD et al (2008) Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology 47(2):563–570. doi:
10.1002/hep.22048PubMedCrossRef
Takahashi M et al (2003) Automated identification of single nucleotide polymorphisms from sequencing data. J Bioinform Comput Biol 1(2):253–265. doi:
10.1142/S021972000300006XPubMedCrossRef
114.
Pauli-Magnus C et al (2004) BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 39(3):779–791. doi:
10.1002/hep.20159PubMedCrossRef
115.
Beuers U (2009) Crosstalk of liver, bile ducts and the gut. Clin Rev Allergy Immunol 36:1–3
PubMedCrossRef
116.
Rieger R et al (2006) Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 27(1):7–16. doi:
10.1016/j.jaut.2006.06.002PubMedCrossRef
117.
Gershwin ME et al (2005) Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 42(5):1194–1202. doi:
10.1002/hep.20907PubMedCrossRef
Milkiewicz P, Heathcote J (2005) Primary biliary cirrhosis in a patient with Turner syndrome. Can J Gastroenterol 19(10):631–633
PubMed
120.
Lakatos LP et al (2002) Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 14(7):733–740. doi:
10.1097/00042737-200207000-00004PubMedCrossRef
121.
Alvaro D et al (2004) Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 41(6):905–912. doi:
10.1016/j.jhep.2004.08.022PubMedCrossRef
122.
Invernizzi P et al (2004) Tamoxifen in treatment of primary biliary cirrhosis. Hepatology 39(4):1175–1176. doi:
10.1002/hep.20164PubMedCrossRef
Padgett KA et al (2009) Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 32(3-4):246–253. doi:
10.1016/j.jaut.2009.02.022PubMedCrossRef
Uibo R, Salupere V (1999) The epidemiology of primary biliary cirrhosis: immunological problems. Hepatogastroenterology 46(30):3048–3052
PubMed
127.
Prince MI et al (2001) The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 34(6):1083–1088. doi:
10.1053/jhep.2001.29760PubMedCrossRef
128.
Ala A et al (2006) Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 43(3):525–531. doi:
10.1002/hep.21076PubMedCrossRef
129.
Zein CO et al (2006) Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment. Hepatology 44(6):1564–1571. doi:
10.1002/hep.21423PubMedCrossRef
Amano K et al (2005) Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 174(9):5874–5883
PubMed
132.
Harada K et al (2001) Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is propionibacterium acnes involved in granuloma formation? Hepatology 33(3):530–536. doi:
10.1053/jhep.2001.22653PubMedCrossRef
133.
Mao TK et al (2005) Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 42(4):802–808. doi:
10.1002/hep.20859PubMedCrossRef
134.
Jones DE et al (2002) Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex. Hepatology 36(3):679–686. doi:
10.1053/jhep.2002.35067PubMedCrossRef
135.
Hopf U et al (1989) Relation between
Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 2(8677):1419–1422. doi:
10.1016/S0140-6736(89)92034-5PubMedCrossRef
136.
Selmi C et al (2003) Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38(5):1250–1257. doi:
10.1053/jhep.2003.50446PubMedCrossRef
137.
Leung PS et al (2003) Is there a relation between Chlamydia infection and primary biliary cirrhosis? Clin Dev Immunol 10(2–4):227–233. doi:
10.1080/10446670310001642429PubMedCrossRef
138.
Abdulkarim AS et al (2004) Primary biliary cirrhosis: an infectious disease caused by
Chlamydia pneumoniae? J Hepatol 40(3):380–384. doi:
10.1016/j.jhep.2003.11.033PubMedCrossRef
139.
Dohmen K et al (2002) Atrophic corpus gastritis and
Helicobacter pylori infection in primary biliary cirrhosis. Dig Dis Sci 47(1):162–169. doi:
10.1023/A:1013292210036PubMedCrossRef
140.
Vilagut L et al (1994) Cross-reactivity of anti-
Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol 21(4):673–677. doi:
10.1016/S0168-8278(94)80117-7PubMedCrossRef
141.
Bogdanos D et al (2008) Primary biliary cirrhosis following
Lactobacillus vaccination for recurrent vaginitis. J Hepatol 49(3):466–473. doi:
10.1016/j.jhep.2008.05.022PubMedCrossRef
142.
Xu L et al (2003) Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A 100(14):8454–8459. doi:
10.1073/pnas.1433063100PubMedCrossRef
143.
Xu L et al (2004) Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 39(1):151–156. doi:
10.1002/hep.20024PubMedCrossRef
144.
Neuberger J et al (1982) Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 306(1):1–4
PubMedCrossRef
145.
Van de Water J et al (1996) Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 24(5):1079–1084. doi:
10.1002/hep.510240517CrossRef
146.
Robertson H et al (2007) Biliary epithelial–mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 45(4):977–981. doi:
10.1002/hep.21624PubMedCrossRef
Mason AL et al (2004) Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 99(12):2348–2355. doi:
10.1111/j.1572-0241.2004.40741.xPubMedCrossRef
151.
Gershwin ME, Selmi C (2004) Apocalypsal versus apocryphal: the role of retroviruses in primary biliary cirrhosis. Am J Gastroenterol 99(12):2356–2358. doi:
10.1111/j.1572-0241.2004.41157.xPubMedCrossRef
152.
Selmi C et al (2004) Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 127(2):493–501. doi:
10.1053/j.gastro.2004.05.033PubMedCrossRef
153.
Cooper CL et al (2004) Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo. Front Biosci 9:338–341. doi:
10.2741/1230PubMedCrossRef
154.
McDermid J et al (2007) Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders. Aliment Pharmacol Ther 26(4):587–595
PubMedCrossRef
155.
Parikh-Patel A et al (2001) Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 33(1):16–21. doi:
10.1053/jhep.2001.21165PubMedCrossRef
156.
Howel D et al (2000) An exploratory population-based case–control study of primary biliary cirrhosis. Hepatology 31(5):1055–1060. doi:
10.1053/he.2000.7050PubMedCrossRef
157.
Rigopoulou EI et al (2006) Lack of association between appendectomy and primary biliary cirrhosis. Scand J Gastroenterol 41(5):573–576. doi:
10.1080/00365520500319633PubMedCrossRef
158.
Bogdanos DP et al (2002) Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol 36(1):14–21. doi:
10.1016/S0168-8278(01)00252-5PubMedCrossRef
159.
Bennion RS et al (1991) The role of
Yersinia enterocolitica in appendicitis in the southwestern United States. Am Surg 57(12):766–768
PubMed
Willerford DM et al (1995) Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3(4):521–530. doi:
10.1016/1074-7613(95)90180-9PubMedCrossRef
Oldstone MB et al (1996) Virus-induced autoimmune disease: transgenic approach to mimic insulin-dependent diabetes mellitus and multiple sclerosis. Curr Top Microbiol Immunol 206:67–83
PubMed
164.
Talbot PJ et al (1996) Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis. Ann Neurol 39(2):233–240. doi:
10.1002/ana.410390213PubMedCrossRef
165.
Wucherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80(5):695–705. doi:
10.1016/0092-8674(95)90348-8PubMedCrossRef
166.
Poole BD et al (2006) Epstein–Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39(1):63–70. doi:
10.1080/08916930500484849PubMedCrossRef
167.
van Eden W et al (1989) A cartilage-mimicking T-cell epitope on a 65 K mycobacterial heat-shock protein: adjuvant arthritis as a model for human rheumatoid arthritis. Curr Top Microbiol Immunol 145:27–43
PubMed
168.
Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347(12):911–920. doi:
10.1056/NEJMra020100PubMedCrossRef
Christen U et al (1994) Identification of the dihydrolipoamide acetyltransferase subunit of the human pyruvate dehydrogenase complex as an autoantigen in halothane hepatitis. Molecular mimicry of trifluoroacetyl-lysine by lipoic acid. Eur J Biochem 223(3):1035–1047. doi:
10.1111/j.1432-1033.1994.tb19082.xPubMedCrossRef
177.
Giordano C et al (1997) Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275(5302):960–963
PubMed
Koga H et al (1997) Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 25(5):1077–1084. doi:
10.1002/hep.510250505PubMedCrossRef
Shimoda S et al (2006) Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory. Gastroenterology 131(2):606–618. doi:
10.1053/j.gastro.2006.05.056PubMedCrossRef
Dubel L et al (1999) Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology 29(4):1013–1018. doi:
10.1002/hep.510290403PubMedCrossRef
185.
Van de Water J et al (1988) The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med 167(6):1791–1799. doi:
10.1084/jem.167.6.1791CrossRef
186.
Leung PS et al (1995) Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology 22(2):505–513
PubMed
187.
Moteki S et al (1996) Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 23(3):436–444. doi:
10.1002/hep.510230307PubMedCrossRef
188.
Surh CD, Coppel R, Gershwin ME (1990) Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. J Immunol 144(9):3367–3374
PubMed
189.
Kita H et al (2002) Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 109(9):1231–1240
PubMed
190.
Kita H et al (2002) Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123(4):1031–1043. doi:
10.1053/gast.2002.36020PubMedCrossRef
191.
Shimoda S et al (1998) Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 102(10):1831–1840. doi:
10.1172/JCI4213PubMedCrossRef
192.
Kita H et al (2002) Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis. Hepatology 36(4 Pt 1):918–926
PubMed
193.
Long SA et al (2001) Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol 167(5):2956–2963
PubMed
194.
Leung PS et al (2003) Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 170(10):5326–5332
PubMed
195.
Leung PS et al (2007) Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 179(4):2651–2657
PubMed
196.
Wakabayashi K et al (2008) Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 48(2):531–540. doi:
10.1002/hep.22390PubMedCrossRef
197.
Lan RY et al (2006) Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 43(4):729–737. doi:
10.1002/hep.21123PubMedCrossRef
198.
Oertelt S et al (2006) Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 177(3):1655–1660
PubMed
199.
Wakabayashi K et al (2006) IL-2 receptor alpha(−/−) mice and the development of primary biliary cirrhosis. Hepatology 44(5):1240–1249. doi:
10.1002/hep.21385PubMedCrossRef
200.
Moritoki Y et al (2009) B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 136(3):1037–1047. doi:
10.1053/j.gastro.2008.11.035PubMedCrossRef
Irie J et al (2006) NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 203(5):1209–1219. doi:
10.1084/jem.20051911PubMedCrossRef
Salas JT et al (2008) Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 134(5):1482–1493. doi:
10.1053/j.gastro.2008.02.020PubMedCrossRef
205.
Beuers U, Boyer JL, Paumgartner G (1998) Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 28(6):1449–1453. doi:
10.1002/hep.510280601PubMedCrossRef
206.
Migliaccio C et al (1998) Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 161(10):5157–5163
PubMed
207.
Migliaccio C et al (2001) Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: the molecule versus the mimic. Hepatology 33(4):792–801. doi:
10.1053/jhep.2001.23783PubMedCrossRef
Fukushima N et al (2002) Characterization of recombinant monoclonal IgA anti-PDC-E2 autoantibodies derived from patients with PBC. Hepatology 36(6):1383–1392
PubMed
210.
Malmborg AC et al (1998) Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis. J Autoimmun 11(5):573–580. doi:
10.1006/jaut.1998.0220PubMedCrossRef
211.
Odin JA et al (2001) Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 108(2):223–232
PubMed
212.
Allina J et al (2006) T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 27(4):232–241. doi:
10.1016/j.jaut.2006.11.004PubMedCrossRef
213.
Leuschner U et al (1985) Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 30(7):642–649. doi:
10.1007/BF01308413PubMedCrossRef
Leuschner U et al (1989) Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 97(5):1268–1274
PubMed
216.
Poupon RE et al (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 324(22):1548–1554
PubMedCrossRef
217.
Heathcote EJ et al (1994) The Canadian Multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19(5):1149–1156. doi:
10.1002/hep.1840190512PubMedCrossRef
218.
Lindor KD et al (1994) Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106(5):1284–1290
PubMed
219.
Pares A et al (2000) Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA– Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 32(4):561–566. doi:
10.1016/S0168-8278(00)80216-0PubMedCrossRef
220.
Combes B et al (1995) A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22(3):759–766
PubMed
221.
Corpechot C et al (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32(6):1196–1199. doi:
10.1053/jhep.2000.20240PubMedCrossRef
222.
Poupon RE et al (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113(3):884–890. doi:
10.1016/S0016-5085(97)70183-5PubMedCrossRef
223.
Hempfling W, Dilger K, Beuers U (2003) Systematic review: ursodeoxycholic acid-adverse effects and drug interactions. Aliment Pharmacol Ther 18(10):963–972. doi:
10.1046/j.1365-2036.2003.01792.xPubMedCrossRef
224.
Beuers U (2006) Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3(6):318–328. doi:
10.1038/ncpgasthep0521PubMedCrossRef
Paumgartner G, Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36(3):525–531. doi:
10.1053/jhep.2002.36088PubMedCrossRef
227.
Festi D et al (2007) Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol 2(2):155–177. doi:
10.2174/157488407780598171PubMedCrossRef
228.
Marschall HU et al (2005) Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129(2):476–485
PubMed
229.
Dilger K et al (2005) No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 41(3):595–602. doi:
10.1002/hep.20568PubMedCrossRef
230.
Poupon RE et al (1993) Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 17(4):599–604. doi:
10.1002/hep.1840170412PubMedCrossRef
231.
Jazrawi RP et al (1994) Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 106(1):134–142
PubMed
232.
Beuers U et al (1993) Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca
++ mechanisms defective in cholestasis. J Clin Invest 92(6):2984–2993. doi:
10.1172/JCI116921PubMedCrossRef
233.
Beuers U et al (2001) Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33(5):1206–1216. doi:
10.1053/jhep.2001.24034PubMedCrossRef
234.
Dombrowski F, Stieger B, Beuers U (2006) Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 86(2):166–174. doi:
10.1038/labinvest.3700371PubMedCrossRef
235.
Wimmer R et al (2008) Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut 57(10):1448–1454. doi:
10.1136/gut.2007.140871PubMedCrossRef
236.
Haussinger D et al (2003) Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis. Gastroenterology 124(5):1476–1487. doi:
10.1016/S0016-5085(03)00274-9PubMedCrossRef
237.
Kubitz R et al (2004) Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase. Gastroenterology 126(2):541–553. doi:
10.1053/j.gastro.2003.11.003PubMedCrossRef
238.
Denk GU et al (2008) Role of mitogen-activated protein kinases in tauroursodeoxycholic acid-induced bile formation in cholestatic rat liver. Hepatol Res 38:717–726
PubMedCrossRef
239.
Noe J et al (2001) Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology 33(5):1223–1231. doi:
10.1053/jhep.2001.24171PubMedCrossRef
240.
Prieto J et al (1993) Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 105(2):572–578
PubMed
241.
Prieto J et al (1999) Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117(1):167–172. doi:
10.1016/S0016-5085(99)70564-0PubMedCrossRef
242.
Medina JF et al (1997) Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 25(1):12–17. doi:
10.1002/hep.510250104PubMedCrossRef
243.
Lindor KD et al (1998) Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol 93(9):1498–1504. doi:
10.1111/j.1572-0241.1998.00470.xPubMedCrossRef
244.
Rost D et al (2004) Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40(3):693–698. doi:
10.1002/hep.20370PubMedCrossRef
245.
Roda E et al (2002) Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis 34(7):523–527. doi:
10.1016/S1590-8658(02)80112-8PubMedCrossRef
246.
Stiehl A et al (1995) Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 23(3):283–289
PubMed
247.
Rodrigues CM et al (1998) A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101(12):2790–2799. doi:
10.1172/JCI1325PubMedCrossRef
Rodrigues CM et al (1998) Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 4(3):165–178
PubMed
250.
Higuchi H, Gores GJ (2003) Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 284(5):G734–G738
PubMed
Schoemaker MH et al (2004) Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39(6):1563–1573. doi:
10.1002/hep.20246PubMedCrossRef
253.
Rust C et al (2009) Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem 284(5):2908–2916. doi:
10.1074/jbc.M804585200PubMedCrossRef
Fickert P et al (2004) Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127(1):261–274. doi:
10.1053/j.gastro.2004.04.009PubMedCrossRef
256.
Svegliati-Baroni G et al (2005) Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology 128(4):1042–1055. doi:
10.1053/j.gastro.2005.01.007PubMedCrossRef
257.
Fiorucci S et al (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127(5):1497–1512. doi:
10.1053/j.gastro.2004.08.001PubMedCrossRef
258.
Fickert P et al (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130(2):465–481. doi:
10.1053/j.gastro.2005.10.018PubMedCrossRef
259.
Yoshikawa M et al (1992) Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16(2):358–364. doi:
10.1002/hep.1840160213PubMedCrossRef
260.
Bergamini A et al (1997) Bile acids with differing hydrophilic–hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells. Hepatology 25(4):927–933. doi:
10.1002/hep.510250423PubMedCrossRef
261.
Calmus Y et al (1992) Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 16(3):719–723. doi:
10.1002/hep.1840160317PubMedCrossRef
262.
Calmus Y et al (1992) Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 103(2):617–621
PubMed
263.
Tanaka H et al (1996) Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 156(4):1601–1608
PubMed
264.
Paumgartner G, Beuers U (2004) Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 8(1):67–81. doi:
10.1016/S1089-3261(03)00135-1 vi
PubMedCrossRef
265.
Lazaridis KN, Gores GJ, Lindor KD (2001) Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 35(1):134–146. doi:
10.1016/S0168-8278(01)00092-7PubMedCrossRef
266.
Trauner M, Graziadei IW (1999) Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13(8):979–996. doi:
10.1046/j.1365-2036.1999.00596.xPubMedCrossRef
267.
Dickson ER et al (1989) Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 10(1):1–7. doi:
10.1002/hep.1840100102PubMedCrossRef
268.
Poupon RE et al (2003) Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39(1):12–16. doi:
10.1016/S0168-8278(03)00192-2PubMedCrossRef
269.
Kaya M, Angulo P, Lindor KD (2000) Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 33(4):537–542. doi:
10.1034/j.1600-0641.2000.033004537.xPubMedCrossRef
270.
Poupon RE et al (1999) Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 29(6):1668–1671. doi:
10.1002/hep.510290603PubMedCrossRef
271.
ter Borg PC et al (2006) Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 101(9):2044–2050. doi:
10.1111/j.1572-0241.2006.00699.xPubMedCrossRef
272.
Koulentaki M et al (2004) Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 49(7–8):1190–1195. doi:
10.1023/B:DDAS.0000037811.48575.daPubMedCrossRef
273.
Eriksson LS et al (1997) Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 32(2):179–186. doi:
10.3109/00365529709000190PubMedCrossRef
274.
Combes B et al (2004) Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 99(2):264–268. doi:
10.1111/j.1572-0241.2004.04047.xPubMedCrossRef
275.
Goulis J, Leandro G, Burroughs AK (1999) Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354(9184):1053–1060. doi:
10.1016/S0140-6736(98)11293-XPubMedCrossRef
276.
Gong Y et al (2008) Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 3:CD000551
PubMed
277.
Gong Y et al (2007) Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 102(8):1799–1807. doi:
10.1111/j.1572-0241.2007.01235.xPubMedCrossRef
278.
Shi J et al (2006) Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101(7):1529–1538. doi:
10.1111/j.1572-0241.2006.00634.xPubMedCrossRef
Mitchison HC et al (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15(3):336–344. doi:
10.1016/0168-8278(92)90065-WPubMedCrossRef
282.
Leuschner M et al (1996) Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 25(1):49–57. doi:
10.1016/S0168-8278(96)80327-8PubMedCrossRef
283.
Arenas F et al (2008) Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 118(2):695–709
PubMed
284.
Leuschner M et al (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117(4):918–925. doi:
10.1016/S0016-5085(99)70351-3PubMedCrossRef
Hempfling W et al (2003) Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38(1):196–202. doi:
10.1053/jhep.2003.50266PubMedCrossRef
287.
Rautiainen H et al (2005) Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41(4):747–752. doi:
10.1002/hep.20646PubMedCrossRef
Talwalkar JA et al (2005) Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 39(2):168–171
PubMed
290.
Holtmeier J, Leuschner U (2001) Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Digestion 64(3):137–150. doi:
10.1159/000048854PubMedCrossRef
Hoofnagle JH et al (1986) Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 91(6):1327–1334
PubMed
293.
Dickson ER et al (1985) Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 312(16):1011–1015
PubMedCrossRef
294.
Kaplan MM et al (1986) A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315(23):1448–1454
PubMedCrossRef
295.
Angulo P et al (2000) Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32(5):897–900. doi:
10.1053/jhep.2000.18663PubMedCrossRef
296.
Kurihara T et al (2000) Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 95(10):2990–2992. doi:
10.1111/j.1572-0241.2000.03220.xPubMedCrossRef
297.
Iwasaki S et al (2008) The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 38(6):557–564. doi:
10.1111/j.1872-034X.2007.00305.xPubMedCrossRef
298.
Tandon P et al (2007) The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 102(7):1528–1536. doi:
10.1111/j.1572-0241.2007.01200.xPubMedCrossRef
299.
Ghent CN, Carruthers SG (1988) Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94(2):488–493
PubMed
300.
Podesta A et al (1991) Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 36(2):216–220. doi:
10.1007/BF01300759PubMedCrossRef
301.
Bachs L et al (1992) Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102(6):2077–2080
PubMed
302.
Bergasa NV et al (1992) A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102(2):544–549
PubMed
303.
Bergasa NV et al (1998) Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27(3):679–684. doi:
10.1002/hep.510270307PubMedCrossRef
304.
Terg R et al (2002) Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 37(6):717–722. doi:
10.1016/S0168-8278(02)00318-5PubMedCrossRef
305.
Browning J, Combes B, Mayo MJ (2003) Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 98(12):2736–2741. doi:
10.1111/j.1572-0241.2003.08662.xPubMedCrossRef
306.
Mayo MJ et al (2007) Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45(3):666–674. doi:
10.1002/hep.21553PubMedCrossRef
307.
Gluud C, Christensen E (2002) Ursodeoxycholic acid for primary biliary irrhosis. Cochrane Database Syst Rev 1:CD000551
PubMed
308.
Prince MI et al (2003) Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther 17(1):137–143. doi:
10.1046/j.1365-2036.2003.01398.xPubMedCrossRef
Theal JJ et al (2005) A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 41(6):1305–1312. doi:
10.1002/hep.20698PubMedCrossRef
311.
ter Borg PC et al (2004) Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial. BMC Gastroenterol 4:13. doi:
10.1186/1471-230X-4-13 ISRCTN88246634
PubMedCrossRef
312.
Talwalkar JA et al (2006) Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci 51(11):1985–1991. doi:
10.1007/s10620-006-9397-5PubMedCrossRef
313.
Newton JL et al (2006) Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 44(1):91–98. doi:
10.1002/hep.21230PubMedCrossRef
314.
Jones DE, Newton JL (2007) An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 25(4):471–476
PubMedCrossRef
Solaymani-Dodaran M et al (2006) Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 131(6):1752–1757. doi:
10.1053/j.gastro.2006.09.012PubMedCrossRef
317.
Lindor KD et al (1995) Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 21(2):389–392
PubMed
Crippin JS et al (1994) Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 89(1):47–50
PubMed
320.
Collier JD, Ninkovic M, Compston JE (2002) Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50(Suppl 1):i1–i9. doi:
10.1136/gut.50.suppl_1.i1PubMedCrossRef
321.
Camisasca M et al (1994) Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 20(3):633–637. doi:
10.1016/0270-9139(94)90098-1PubMedCrossRef
Pereira SP et al (2004) Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther 19(5):563–570. doi:
10.1111/j.1365-2036.2004.01890.xPubMedCrossRef
324.
Kocjan T, Prelevic GM (2003) Hormone replacement therapy update: who should we be prescribing this to now? Curr Opin Obstet Gynecol 15(6):459–464. doi:
10.1097/00001703-200312000-00001PubMedCrossRef
325.
Hulley S et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280(7):605–613. doi:
10.1001/jama.280.7.605PubMedCrossRef
326.
Rossouw JE et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333. doi:
10.1001/jama.288.3.321PubMedCrossRef
Floreani A et al (2007) A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. Dig Liver Dis 39(6):544–548. doi:
10.1016/j.dld.2007.02.005PubMedCrossRef
329.
Zein CO et al (2005) Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42(4):762–771. doi:
10.1002/hep.20866PubMedCrossRef
330.
Guanabens N et al (2003) Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 98(10):2268–2274
PubMed
Hirschfield GM, Liu X et al (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 Variants. N Engl J Med 360(24):2544–2555
PubMedCrossRef
Über diesen Artikel
Titel
Primary biliary cirrhosis
Autoren:
Simon Hohenester Ronald P. J. Oude-Elferink Ulrich Beuers
Entzündliche Gelenkerkrankungen – mit Fallbeispielen
Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …
Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.
Herausgeber:
Santiago Ewig
Newsletter
Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.